Mesenchymal cells vs standard care for steroid-resistant graft-versus-host disease
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial studies a type of immune-support cell therapy (mesenchymal stromal cells) compared with the best available standard treatment for acute graft-versus-host disease (aGvHD) that does not respond to steroids. It may help by calming an overactive immune reaction after a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously had an allogeneic stem cell transplant (for blood cancers or certain non-cancer blood/immune conditions)
- You currently have acute graft-versus-host disease that is Grade 2 to Grade 4
- Your aGvHD did not respond to first-line steroid treatment (it worsened quickly or did not improve, or only partially improved after a longer steroid-based treatment)
- Your expected survival is more than 28 days
- You are age 12 or older
- Your underlying disease is not clearly coming back or progressing at screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental cell therapy called VUM02 for people who have graft-versus-host disease (GvHD) after a stem cell transplant that hasn't improved with standard steroid treatment. The goal is to see if this new treatment can help control GvHD symptoms and improve outcomes.
This trial tests whether moxibustion—a traditional Chinese medicine technique using heat from burning mugwort—can help treat acute graft-versus-host disease (a complication after bone marrow transplant) that hasn't responded to steroid drugs. If you've had a stem cell transplant and developed this condition that won't go away with standard treatment, this study may be for you.
This study tests a new cell therapy (CK0802) for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard steroid treatment. The treatment aims to control the immune response causing GVHD, potentially reducing symptoms and improving outcomes.
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
This study tests whether an experimental cell therapy called iMSC can help prevent graft-versus-host disease (a common complication after a stem cell transplant). It is given soon after your transplant, within 5 days of enrolling, and aims to reduce the chance of this serious condition.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Hear when a new Steroid-refractory Acute Graft-versus-host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.